Economic Evaluation of a Novel MicroRNA-Based Assay to Determine Risk of Late Genitourinary Radiation Toxicity in Patients With Prostate Cancer.

ABSTRACT:

Background

Prostate cancer is one of the most common malignancies in men, and radiation therapy, most often stereotactic body radiation therapy or conventionally fractionated radiotherapy, is a standard curative treatment for advanced cases. Although genitourinary toxicity is a known side effect, with acute symptoms typically resolving and late toxicity causing lasting harm, individual risk varies substantially. However, no validated tool exists to predict patient-specific toxicity across radiation modalities, leaving treatment decisions to be made without personalized risk insights.

Objective

The goal of this analysis was to estimate changes in cost and quality of life associated with reductions in late genitourinary toxicity attributable to personalized radiation therapy i

SUBMITTER: Cooper JT 

PROVIDER: S-EPMC12714312 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature